Content deleted Content added
No edit summary |
m →Monitoring: copyedit |
||
Line 105:
More recently, a regular [[echocardiogram]] is also recommended to detect [[myocarditis]].
The manufacturers of both the brand and generic clozapine are required by the FDA to track white blood cells counts for patients receiving clozapine, and pharmacies are required to obtain a copy of the [[Full blood count|CBC]] prior to dispensing the medication to the patient. The purpose of the monitoring system is to prevent rechallenge with clozapine in patients with a history of clozapine-induced agranulocytosis and to detect [[leukopenia|leukopenic]] events among patients taking clozapine. In other countries (e.g. in Europe), restrictions have been eased.
==Dosage==
| |||